External beam radiotherapy for clinically node-negative, localized hormone-refractory prostate cancer: impact of pretreatment PSA value on radiotherapeutic outcomes

Akimoto, Tetsuo; Kitamoto, Yoshizumi; Saito, Junichi; Harashima, Koichi; Nakano, Takashi; Ito, Kazuto; Yamamoto, Takumi; Kurokawa, K; Yamanaka, Hidetoshi; Takahashi, Mitsuhiro; Mitsuhashi, Norio; Niibe, Hideo

doi:10.1016/j.ijrobp.2003.10.033

Cited by 25 publications

(16 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several reports have also indicated that radical radiotherapy had an excellent local control rate for these tumors (20,32 Abbreviations as in Table 3. Values in parentheses are percentages.…”

Section: Discussionmentioning

confidence: 99%

External Beam Radiotherapy for Clinically Localized Hormone-Refractory Prostate Cancer: Clinical Significance of Nadir Prostate-Specific Antigen Value Within 12 Months

Ogawa

Nakamura

Sasaki³

et al. 2009

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

External Beam Radiotherapy for Clinically Localized Hormone-Refractory Prostate Cancer: Clinical Significance of Nadir Prostate-Specific Antigen Value Within 12 Months

Ogawa

Nakamura

Sasaki³

et al. 2009

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

“…In an earlier Japanese report containing data from 61 patients (14), the 5-year PFS rate was 43.5%. Another study from Japan (11) presented results from 53 patients: The 3-year clinical relapse- free survival rate was 78%, and 15 patients developed clinical metastases during a median follow-up of 35 months (11). An Italian study published at the same time reported the data from 29 patients, 24 (83%) of whom had developed biochemical failure after a median of 9.2 months from EBRT (13).…”

Section: Discussionmentioning

confidence: 99%

“…No consensus on the treatment of nonmetastasized castration-resistant prostate cancer has yet been reached. Few published studies have evaluated RT for castration-resistant prostate cancer (9)(10)(11)(12)(13)(14)(15)(16). The aim of the present study was to evaluate the outcome of RT among patients who underwent androgen-deprivation therapy as a primary therapy for non-metastatic prostate cancer with progression to castration-resistant disease at our institution between 2000 and 2010.…”

Section: Introductionmentioning

confidence: 99%

External beam radiation for the treatment of castration-resistant prostate cancer following primary hormonal therapy with androgen ablation: Analysis and outcome of 21 patients

Kuusk

Pulliainen

Vaarala

2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract.Patients who undergo early androgen-deprivation therapy for prostate cancer may eventually develop castrationresistant prostate cancer. However, no optimal treatment for non-metastasized castration-resistant prostate cancer has yet been established. In the present retrospective, singleinstitutional study, the radiotherapy (RT) outcomes were evaluated in patients who underwent androgen-deprivation therapy for non-metastatic prostate cancer and subsequently developed castration-resistant disease. Following a thorough chart review, the data of 21 patients with castration-resistant prostate cancer who were treated between 2000 and 2010 with external beam radiation therapy (EBRT) at a prostate radiation dose of >45 Gy were evaluated. Of the 21 patients, 16 (76%) developed biochemical recurrence after RT, with a mean time to biochemical recurrence of 17 months. A total of 18 patients succumbed to the disease during follow-up, with a mean survival of 3 years after RT. A radiation dose of >66 Gy was associated with a longer time to biochemical recurrence after RT (P=0.011) and a longer survival, compared with a dose of ≤66 Gy (P= 0.028). The mean overall survival time after RT was 42 months and did not depend on the primary hormonal treatment. Prostate-specific survival time was negatively associated with the Gleason score at diagnosis. The prostate-specific antigen (PSA) concentration prior to RT was a prognostic factor for biochemical recurrence of prostate cancer after RT, as well as for prostate cancer-specific survival. Finally, the multivariate analysis revealed that age, PSA concentration prior to RT and a high Gleason score were independent prognostic factors for prostate cancer-specific survival. Overall, our study findings demonstrated that disease progression was common after EBRT for castration-resistant prostate cancer and that survival was limited. However, young patients and those with low-risk disease at the time of diagnosis may benefit from RT. IntroductionProstate cancer is the most common cancer among European men, comprising 12% of all new cancer cases and 5% of all cancer deaths in 2012 (1). There is no evidence that one radical treatment for localized disease is more effective compared with another (2). In a recently published randomized trial, it was demonstrated that radical prostatectomy and radiotherapy (RT) achieved comparable disease control after a 10-year follow-up (3). External beam radiation therapy (EBRT) is a treatment option available at different stages of non-metastatic prostate cancer (4). Androgen-deprivation therapy has also been used as primary treatment for localized prostate cancer (5), leading to apoptotic regression of androgen-dependent tumors. Possible androgen-deprivation therapy regimens include orchiectomy, gonadotropin hormone-releasing hormone (GnRH) agonists, GnRH antagonists and androgen receptor antagonists (6). Use of early androgen-deprivation therapy for prostate cancer may lead to the development of castration-resistant prostate cancer. The median time...

show abstract

“…Stråleterapi kan gi god lokal tumorkontroll også ved hormonrefraktaer prostatakreft (Akimoto et al, 2004,Lankford et al, 1995. Sjansen for tumorrespons er større ved lavere tumorvolum.…”

Section: Stråleterapiunclassified

Re: Ulike retningslinjer for behandling av prostatakreft

Solberg¹,

Angelsen²,

Berge³

et al. 2015

Tidsskriftet

View full text Add to dashboard Cite

External beam radiotherapy for clinically node-negative, localized hormone-refractory prostate cancer: impact of pretreatment PSA value on radiotherapeutic outcomes

Cited by 25 publications

References 30 publications

External Beam Radiotherapy for Clinically Localized Hormone-Refractory Prostate Cancer: Clinical Significance of Nadir Prostate-Specific Antigen Value Within 12 Months

External Beam Radiotherapy for Clinically Localized Hormone-Refractory Prostate Cancer: Clinical Significance of Nadir Prostate-Specific Antigen Value Within 12 Months

External beam radiation for the treatment of castration-resistant prostate cancer following primary hormonal therapy with androgen ablation: Analysis and outcome of 21 patients

Re: Ulike retningslinjer for behandling av prostatakreft

Contact Info

Product

Resources

About